Navigation Links
Introgen Reports Updated Phase 2 Advexin Data Correlating Improved,Survival, Tumor Responses and Predictive p53 Biomarker

CHICAGO--(BUSINESS WIRE)--Jun 4, 2007 - Introgen Therapeutics, Inc. (NASDAQ: INGN) and the Company's clinical collaborators today reported updated Phase 2 data demonstrating a significant correlation between abnormal p53, tumor responses and increased survival following ADVEXIN(R) therapy in patients with recurrent squamous cell carcinoma of the head and neck. The data (Abstract #6057) were presented today at the annual meeting of the American Society of Clinical Oncology in Chicago.

Tumor responses were assessed in 112 patients with recurrent head and neck cancer who received ADVEXIN. Overall, the percentages of patients with tumor responses defined by reductions in bi-dimensional tumor area on CT scan of 50 percent, 25 percent, 10 percent or stable disease for more than 2 treatment cycles were 6 percent, 7 percent, 12 percent and 22 percent, respectively. Median survival for these responder populations were 41, 17, 15 and 10 months, respectively. There was a statistically significant increase in median survival for each of the responder populations compared to the 6 month median survival of the non-responders (p less than 0.0016).

"The 41 month median duration of survival for the patients with a 50 percent or greater reduction in tumor size is very impressive and significantly greater than the six month median survival of non-responders that is typical for patients with recurrent tumors," said John Nemunaitis, M.D., Medical Director, Mary Crowley Medical Research Center. "Our findings are also consistent with a growing body of data that even smaller reductions in tumor size are clinically meaningful and are associated with increased survival."

The presentation also included data demonstrating that the predictive abnormal p53 biomarker was associated with a statistically significant increase in tumor responses to ADVEXIN therapy. A reduction in tumor size was observed in 40 percent of patients wi
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Introgen Reports Promising Phase 1/2 Clinical Results With INGN 241 in Patients With Advanced Solid Tumors
2. Introgens Advexin Demonstrates Clinical Benefit in Inherited Cancer
3. Introgen and Clinical Collaborators to Report New Results with Advanced-Stage Cancer Therapies at Upcoming Medical Meetings
4. Preclinical Studies Identify Novel Approach for Enhancing the Anticancer Activity of Introgens INGN 241
5. Introgen Presents ADVEXIN Biomarker Data at Major Cancer Conference
6. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
7. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
10. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
11. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
Post Your Comments:
(Date:7/30/2014)... 30, 2014 Reportlinker.com announces that a ... catalogue: mHealth and Home Monitoring – ... Executive summary mHealth can ... better outcomes, decreased costs and improved sustainability of ... is still in an early stage, but on ...
(Date:7/30/2014)... and KISSING, Germany , ... distributor of a single use and computer-assisted ("robotic") colonoscopy ... Shamir , a worldwide recognized medical device executive, as ... Mr. Shamir is a highly respected global visionary ... assignment he served as President and Chief Executive Officer ...
(Date:7/30/2014)... DIEGO , July 30, 2014  Eisai Inc. and ... that an article based on post-hoc analyses from the three ... While on Lorcaserin, Diet, and Exercise as a Predictor of ... issue of Obesity , the official peer reviewed journal ... to identify whether there is an early treatment milestone that ...
Breaking Medicine Technology:mHealth and Home Monitoring - 6th Edition 2mHealth and Home Monitoring - 6th Edition 3mHealth and Home Monitoring - 6th Edition 4mHealth and Home Monitoring - 6th Edition 5mHealth and Home Monitoring - 6th Edition 6mHealth and Home Monitoring - 6th Edition 7mHealth and Home Monitoring - 6th Edition 8mHealth and Home Monitoring - 6th Edition 9mHealth and Home Monitoring - 6th Edition 10mHealth and Home Monitoring - 6th Edition 11invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 2invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 4Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 5Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 6Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 7
... Global safety equipment manufacturer MSA (NYSE: MSA ... air-purifying respirator (APR) line in two U.S. factories in ...  The respirators, which include half-mask and full-facepiece models, are ... health officials involved with remediation and containment efforts associated ...
... March 30, 2011 Generex Biotechnology Corporation ( www.generex.com ... a press conference earlier today at the NASDAQ Marketsite ... plan for the Company,s future growth.  A video of ... Generex website. (Logo: https://photos.prnewswire.com/prnh/20110106/NY25057LOGO-b) ...
Cached Medicine Technology:MSA Increases Production of Air-Purifying Respirators to Help Meet Increased Demand from Japan 2Generex Unveils Strategic Development Plan 2Generex Unveils Strategic Development Plan 3Generex Unveils Strategic Development Plan 4Generex Unveils Strategic Development Plan 5Generex Unveils Strategic Development Plan 6Generex Unveils Strategic Development Plan 7Generex Unveils Strategic Development Plan 8Generex Unveils Strategic Development Plan 9
(Date:7/30/2014)... 30, 2014 2014 Deep ... Industry” is a professional and in-depth research ... report provides basic Chitosan information, including Chitosan ... as well as industry overview. This research ... market as well as global industry analysis ...
(Date:7/30/2014)... -- For patients with asthma, just believing an odor ... for at least 24 hours, a new study indicates. ... what you think you smell," study author Cristina Jaen, ... said in a Monell news release. "Asthmatics ... expect that an odor is harmful, our bodies react ...
(Date:7/30/2014)... jockeying for supremacy within a cancerous tumor, the most ... fastest, researchers at Dana-Farber Cancer Institute report in a ... journal Nature . The findings have important ... the study authors explained: Doctors need to ascertain which ... metastasis and select drugs that target the critical genes ...
(Date:7/30/2014)... July 30, 2014 On July 29, ... the Indian Institute of Public Health, Gandhinagar released a ... India, Volume II: The Way Forward .” The report ... on Policies and Practices to Improve Nutrition Security in ... Father of the Green Revolution" and chair of the ...
(Date:7/30/2014)... Shabaikai is an ambitious historical novel, which ... Indians located on the shores of Russian River in ... ‘crooked snake’. Clarkson takes the reader into 20th Century ... prohibition and organized crime, providing a glimpse into the ... powerful men in the world convene the last two ...
Breaking Medicine News(10 mins):Health News:Chitosan Market & Sialic Acid Industry Research Analysis for World, China Regions Available at DeepResearchReports.com 2Health News:Chitosan Market & Sialic Acid Industry Research Analysis for World, China Regions Available at DeepResearchReports.com 3Health News:Chitosan Market & Sialic Acid Industry Research Analysis for World, China Regions Available at DeepResearchReports.com 4Health News:Even Thinking an Odor is Harmful May Spur Asthma Symptoms 2Health News:Target growth-driving cells within tumors, not fastest-proliferating cells 2Health News:Target growth-driving cells within tumors, not fastest-proliferating cells 3Health News:New Report on Integrated Health and Microfinance in India Shows the Way Forward 2Health News:New Report on Integrated Health and Microfinance in India Shows the Way Forward 3Health News:New Report on Integrated Health and Microfinance in India Shows the Way Forward 4Health News:Bill E. Clarkson Releases Debut Fact-Based Novel, Shabaikai 2
... The FDA has warned the consumer against the multiple ... issued after the FDA learned about the 24 related ... ,The FDA received information that counterfeit versions of ... web sites. Xenical manufactured by Hoffman-La Roche, Inc. help ...
... but new studies have revealed that coffee can be quite beneficial. ... cancers too. Some experts believe that it can also lower the ... ,Antioxidants in coffee help control the cell damage that can ... source of chlorogenic acid, which has been shown in animal experiments ...
... genes by American scientists has revealed a startling find. Around ... that is linked to// the risks of developing heart diseases. ... that is connected with diabetes. ,The findings, ... so many people have heart disease even if they do not ...
... countries met Friday to formally adopt a 24-page report on ... five days of heated debate to reaching a consensus on ... Friday," said Carloa Traverso Saibante, information officer for the UN ... IPCC report is formally adopted, it will be released to ...
... to mobilise US congressmen and senators against Indian authorities denying ... a case relating to his crusade against the corrupt healthcare ... of alleged wrongful treatment in India in May 1988, said: ... in US and will ask them to raise this issue ...
... Brazil government is up against giant drug manufacturers- Merck &Co. ... to the Brazilian government, there is no call to charge ... when Thailand is paying 65 cents for the same. ... last November. Last week the government declared the drug a ...
Cached Medicine News:Health News:New Health Drink—Coffe 2Health News:Gene Mutations Leave Caucasians Prone To Heart Diseases And Diabetes 2Health News:Climate Talks Reach Consensus in Bangkok 2Health News:NRI Threatens to Move US Congress for Justice in India 2Health News:Brazil Government In Contention With Merck Over Anti-AIDS Drug 2
... Unparalleled Comfort Pick one of our pipettors ... the trigger and ejector positionsright where they should ... are ergonomically designed to help avoid repetitive stress ... Productivity In The Palm Of Your Hand ...
... multichannel has the same innovative ... model. The same universal handle ... five single channel tip cone ... recharge and storage stand with ...
... The Research pro Electronic Pipette is ideal ... laboratory. Its easy-to-follow display, ergonomically-placed operating buttons, ... dispensing, reverse pipetting and diluting make this ... simple functions of a manual pipette without ...
... Comfort Pick one of our pipettors up ... trigger and ejector positionsright where they should beeven ... ergonomically designed to help avoid repetitive stress injuries ... In The Palm Of Your Hand Start ...
Medicine Products: